<!DOCTYPE html>
<html lang="en">
<head><!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-N4XZHNC');</script> <!-- End Google Tag Manager -->

<title>Olaparib: Mechanism of Action, Adverse Effects, and Contraindications</title>
  <meta charset="utf-8">

  <link href="urology2.css" rel="stylesheet">

<meta name="keywords" content="Olaparib, Mechanism of Action, Adverse Effects, Contraindications, dosage" >
<meta name="description" content="Pharmacological profile of the PARP Inhibitor Olaparib with Mechanism of Action, Adverse Effects and Contraindications,  from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
 </head>

<body><!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N4XZHNC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="https://www.urology-textbook.com/index.html">
	   <p><span style="font-size: 1.2em;">Urology Textbook</span><br>
       
       <span style="font-size: 0.8em;">Clinical Essentials</span>
       <br>
       <span style="font-size: 0.6em;">By Dirk Manski, MD</span></p>
    </a>  
</header>
<main> 
<article>
<nav role="navigation">
<div id="menuToggle">
<input type="checkbox" id="menuCheckbox" />
     <span></span>
    <span></span>
    <span></span>
<ul id="menu">
<li>
        <a href="https://www.urology-textbook.com/anatomy.html">
          <label for="menuCheckbox" onclick="this.parentNode.click();">Anatomy</label>
        </a>
      </li>
<li><a href="https://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="https://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="https://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="https://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="https://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="https://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="https://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="https://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="https://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="https://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="https://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="https://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="https://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="https://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="https://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="https://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="https://www.urology-textbook.com/links.html">Links</a></li>
</ul>

</div>
</nav>

<p id="brotkrumen">&nbsp;You are here: <a href="https://www.urology-textbook.com/index.html">Urology Textbook</a> &gt; <a href="https://www.urology-textbook.com/pharmacology.html">Drugs in Urology</a> &gt; Olaparib</p>

<h1>Olaparib: Mechanism of Action, Adverse Effects, and Contraindications</h1>

<h2>Mechanism of Action of PARP Inhibitors:</h2>
<p>The poly-ADP-ribose polymerase (PARP) enzyme participates in cellular DNA repair. Another mechanism for DNA repair is homologous recombinational repair (HRR); well-known genes involved in HRR include, among others, BRCA1 and BRCA2 (breast cancer). Inhibition of PARP by olaparib prevents DNA repair, and tumor cells, which frequently undergo division and are subject to high DNA turnover, are particularly damaged and undergo <a href="https://www.urology-textbook.com/apoptosis.html">apoptosis</a>. PARP inhibition by olaparib is especially effective when HRR is also impaired by mutations.</p>

<h2>Indications for Olaparib</h2>
<p>Olaparib (Lynparza) is approved as monotherapy for <a href="https://www.urology-textbook.com/prostate-cancer-castration-resistant.html">metastatic castration-resistant prostate cancer (mCRPC)</a> in patients harboring BRCA1/2 mutations (de Bono et al., 2020), who have progressed under newer hormonal therapy: it has shown improved progression-free survival (7 vs. 4 months) and improved overall survival (19 vs. 15 months). </p>

<p>In addition, the combination of olaparib, <a href="https://www.urology-textbook.com/abiraterone.html">abiraterone</a>, and prednisone is approved for first-line therapy in mCRPC when <a href="https://www.urology-textbook.com/docetaxel.html">docetaxel chemotherapy</a> is not indicated or feasible. In Europe, the European Medicines Agency (EMA) has not restricted the approval of the olaparib/abiraterone combination to only patients with BRCA mutations (in contrast to U.S. FDA approval).</p>

<h2>Pharmacokinetics of Olaparib</h2>
<p>Olaparib is well absorbed orally, regardless of food intake; it has a half-life of approximately 15 hours. It is metabolized hepatically via CYP3A4 and CYP3A5, and its metabolites are excreted in roughly equal proportions via urine and feces.</p>

<h2>Adverse Effects of Olaparib</h2>
<p>The most common adverse events (of all grades) are anemia, neutropenia, thrombocytopenia, and nausea. Below are the frequencies of grade 3 and 4 events (very common &gt;10%, common 1–10%, and rare &lt;1%):</p>
<ul>
<li>Hematologic: anemia (14%), thrombocytopenia (2%), and neutropenia (5%).</li>
<li>Gastrointestinal tract: nausea and vomiting (6%), less frequently stomatitis, diarrhea, or abdominal pain.</li>
<li>Respiratory tract: rare dyspnea or cough, very rarely severe pneumonitis.</li>
<li>Skin: rare rash, very rare dermatitis.</li>
<li>Other adverse events: fatigue (6%) and thromboembolic events.</li>
</ul>

<h3>Drug Interactions of Olaparib</h3>
<p>Avoid concurrent administration of CYP3A4 inhibitors (e.g., ketoconazole, <a href="https://www.urology-textbook.com/azithromycin.html">azithromycin</a>); alternatively, a substantial dose reduction is required. Avoid also concurrent use of CYP3A4 inducers (e.g., rifampicin).</p>

<h2>Contraindications of Olaparib</h2>
<ul>
<li>Severe hepatic impairment (Child-Pugh class C)</li>
<li><a href="https://www.urology-textbook.com/chronic-kidney-disease.html">Severely reduced kidney function</a> (glomerular filtration rate &lt; 30 mL/min)</li>
<li>Persistent grade 3 or 4 adverse events despite dose reduction</li>
</ul>

<h2>Dosage of Olaparib</h2>
<p>The recommended regimen is 300 mg Olaparib taken twice daily (150 mg tablets 2-0-2), which corresponds to a total daily dose of 600 mg. In the event of adverse effects, after a treatment pause (with weekly laboratory monitoring) and normalization, reduce the dose stepwise to daily doses of 500 mg or 400 mg. In cases of moderately reduced kidney function (GFR 30&ndash;50 mL/min), reduce the daily dose to 400 mg. If grade 3 or higher adverse events recur under reduced dosage, discontinue olaparib permanently.</p>

<h4>Monitoring During Therapy:</h4>
<p>During the first month, monitor the differential blood count weekly, then monthly thereafter. Monthly assessments should include electrolytes, liver function tests, <a href="https://www.urology-textbook.com/creatinine-serum-blood-test.html">creatinine</a>, skin examination, blood pressure, and inspection of the oral cavity.</p>

<h3>Trade Name</h3>
<p>Lynparza</p>


<div id="ad-footer">
<!-- ad-footer -->
<ins class="adsbygoogle"
     style="display:inline-block;width:500px;height:250px"
     data-ad-client="ca-pub-9284927104423861"
     data-ad-slot="8746163219"></ins>
 <script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>
</div>
<br><table id="navigation_unten">
<tr>
 
<td><a href="https://www.urology-textbook.com/pazopanib.html">Pazopanib</a></td>
<td><a class="nav4" href="https://www.urology-textbook.com/index-urology.html">Index</a></td>
<td><a class="nav3" href="https://www.urology-textbook.com/nirapanib.html">Nirapanib</a></td>
 
</tr>
</table>

<br>
<br>
Index: <a href="https://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="https://www.urology-textbook.com/index-urology-a.html">A</a> <a href="https://www.urology-textbook.com/index-urology-b.html">B</a> <a href="https://www.urology-textbook.com/index-urology-c.html">C</a> <a href="https://www.urology-textbook.com/index-urology-d.html">D</a> <a href="https://www.urology-textbook.com/index-urology-e.html">E</a> <a href="https://www.urology-textbook.com/index-urology-f.html">F</a> <a href="https://www.urology-textbook.com/index-urology-g.html">G</a> <a href="https://www.urology-textbook.com/index-urology-h.html">H</a> <a href="https://www.urology-textbook.com/index-urology-i.html">I</a> <a href="https://www.urology-textbook.com/index-urology-j.html">J</a> <a href="https://www.urology-textbook.com/index-urology-k.html">K</a> <a href="https://www.urology-textbook.com/index-urology-l.html">L</a> <a href="https://www.urology-textbook.com/index-urology-m.html">M</a> <a href="https://www.urology-textbook.com/index-urology-n.html">N</a> <a href="https://www.urology-textbook.com/index-urology-o.html">O</a> <a href="https://www.urology-textbook.com/index-urology-p.html">P</a> <a href="https://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="https://www.urology-textbook.com/index-urology-r.html">R</a> <a href="https://www.urology-textbook.com/index-urology-s.html">S</a> <a href="https://www.urology-textbook.com/index-urology-t.html">T</a> <a href="https://www.urology-textbook.com/index-urology-u.html">U</a> <a href="https://www.urology-textbook.com/index-urology-v.html">V</a> <a href="https://www.urology-textbook.com/index-urology-w.html">W</a> <a href="https://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<br>
<h3>References</h3>

<p>J. de Bono <i>et al.</i>, “Olaparib for Metastatic Castration-Resistant Prostate Cancer.,” <i>NEJM</i>, 2020.</p>

<p>J. Mateo <i>et al.</i>, “Olaparib in patients with metastatic castration-resistant <a href="https://www.urology-textbook.com/prostate-cancer.html">prostate cancer</a> with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.,” <i>Lancet Oncol</i>, vol. 21, no. 1, pp. 162–174, 2020.</p>

<p>F. Saad, N. W. Clarke, M. Oya, N. Shore, G. Procopio, and J. Guedes, “Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.,” <i>Lancet Oncol.</i>, vol. 24, no. 10, pp. 1094–1108, 2023.</p>


<br>
<br>
<p><img src="https://images0.urology-textbook.com/deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/olaparib.html">Mechanismus, Nebenwirkungen, Kontraindikationen und Dosierung von Olaparib</a></p>  

  <br> <br><h3>Urology-Textbook.com – Choose the Ad-Free, Professional Resource</h3>
<p>This website is designed for physicians and medical professionals. It presents diseases of the genital organs through detailed text and images. Some content may not be suitable for children or sensitive readers. Many illustrations are available exclusively to Steady members. Are you a physician and interested in supporting this project? <a href="https://steady.page/de/urology/about">Join Steady to unlock full access</a> to all images and enjoy an ad-free experience. Try it free for 7 days&mdash;no obligation. </p>

<p><strong>New release:</strong> The first edition of the Urology Textbook as an e-book&mdash;ideal for offline reading and quick reference. With over 1300 pages and hundreds of illustrations, it’s the perfect companion for residents and medical students. After your 7-day trial has ended, you will receive a download link for your exclusive e-book.</p>
</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="https://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="https://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul>
	<a class="steady-login-button" data-size="medium" data-language="en" style="display: none;"></a>
</footer>
</body>
</html>
